C17orf60 Activators
Forskolin, Isoproterenol, and db-cAMP, through their impact on cAMP levels, can orchestrate a diverse set of cellular responses, thereby influencing the activity of proteins such as C17orf60. Ionomycin and PMA directly target intracellular signaling by altering ion concentrations and activating protein kinases, respectively. Such alterations can shift the balance of protein activities within the cell, potentially impacting those proteins that are functionally linked with C17orf60. Retinoic acid and 5-Azacytidine operate at the genomic level, modifying gene expression patterns that could dictate the availability and functionality of C17orf60 within the cellular milieu.
Lithium chloride, Insulin, and Rapamycin each target specific signaling pathways, namely GSK-3, insulin receptor signaling, and mTOR pathways. These pathways are integral to the regulation of cellular growth, metabolism, and survival, and their modulation could influence the activity of a broad spectrum of proteins, including C17orf60. Sodium butyrate, by affecting histone acetylation, can also induce changes in gene expression that might impact the cellular role of C17orf60.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Increases intracellular calcium, potentially affecting calcium-dependent proteins and possibly pathways involving C17orf60. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Alters gene expression through nuclear receptors, which could affect the expression or function of C17orf60. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Inhibits DNA methyltransferases, possibly leading to the upregulation of genes encoding proteins related to the function of C17orf60. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates PKC, influencing multiple signaling pathways, some of which may intersect with C17orf60's function. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A cAMP analog that activates PKA, potentially affecting signaling pathways related to C17orf60. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Modulates glycogen synthase kinase-3 (GSK-3) activity, potentially impacting pathways related to C17orf60. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Activates the insulin receptor pathway, which could intersect with signaling pathways involving C17orf60. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Inhibits histone deacetylases, potentially affecting gene expression and protein function related to C17orf60. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A beta-adrenergic agonist that raises cAMP levels, possibly influencing pathways associated with C17orf60. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, which could alter signaling pathways and potentially affect the activity of C17orf60. | ||||||